TCGA-70-6722-01A-11R-1820-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 47
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- INTERFERON_ALPHA_RESPONSE+0.530
- G2M_CHECKPOINT+0.510
- INTERFERON_GAMMA_RESPONSE+0.500
- TGF_BETA_SIGNALING+0.500
- MYC_TARGETS_V2+0.490
- ANGIOGENESIS+0.480
- APICAL_JUNCTION+0.450
- TNFA_SIGNALING_VIA_NFKB+0.450
- MITOTIC_SPINDLE+0.440
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.190
- OXIDATIVE_PHOSPHORYLATION-0.180
- BILE_ACID_METABOLISM-0.160
- KRAS_SIGNALING_DN-0.140
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.120
- SPERMATOGENESIS-0.110
- XENOBIOTIC_METABOLISM-0.090
- FATTY_ACID_METABOLISM-0.060
- MYOGENESIS+0.080
- PEROXISOME+0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-98-8020-01A-11R-2247-07 | — | cohortSQ1 | 0.931 |
| 2 | TCGA-HQ-A5NE-01A-12R-A28M-07 | — | — | 0.926 |
| 3 | SRR934962 | — | — | 0.926 |
| 4 | TCGA-50-6595-01A-12R-1858-07 | — | cohortA1 | 0.917 |
| 5 | TCGA-E7-A97P-01A-11R-A38B-07 | — | — | 0.916 |
| 6 | SRR934782 | — | — | 0.913 |
| 7 | DB34442C-1882-495A-A2F0-2427116A1FAF | — | — | 0.912 |
| 8 | SRR10900575 | — | — | 0.910 |
| 9 | SRR934760 | — | — | 0.909 |
| 10 | SRR934816 | — | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.440 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.440 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| APOPTOSIS | 0.410 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.410 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.400 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |